Hairy cell leukemia: Past, present and future

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Hairy cell leukemia (HCL) is a rare B-cell malignancy with distinct clinical and pathological features.
• Understanding the molecular pathogenesis of HCL has evolved significantly over time.

Observation:

• Therapeutic milestones in HCL management have progressed from traditional chemotherapy to more targeted approaches.
• Recent advances have identified key genetic mutations driving HCL, notably the BRAF V600E mutation.

Findings:

• The BRAF V600E mutation is a frequent finding in HCL, offering a specific molecular target.
• Other genetic alterations are also being investigated for their role in HCL development and progression.

Implications:

• Targeted therapies directed at specific molecular abnormalities, such as BRAF inhibitors, are revolutionizing HCL treatment.
• Future research focusing on molecular findings promises to further refine treatment strategies and improve long-term outcomes for HCL patients.